It has been pointed out that mutations in the new coronavirus (SARS-CoV-2) are behind infection explosions in the UK and South Africa. A number of mutations have occurred, but a mutation common to these has already been shown to be N501Y.
A group of The University of Texas Medical Branch, Galveston TX has reported on how the mutation affects the effects of Pfizer’s vaccine, Tozinameran (BNT162b2, a nucleoside modified RNA vaccine).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805448/
A comparative experiment using N501 and Y501, which is the genetic background of N501, was done by measuring 50% plaque reduction neutralization titers for N501 and Y501 viruses using sera from 20 people collected 2 weeks and 4 weeks after administration of the vaccine. As a result, it was reported that almost the same neutralization titers were obtained.
